Renalyx Launches India’s First Indigenous AI-Powered Hemodialysis Machine, Plans INR 800 Cr Investment

Renalyx Launches India’s First Indigenous AI-Powered Hemodialysis Machine, Plans INR 800 Cr Investment

The Bengaluru-based company has also announced plans to invest INR 800 Cr over the next four years to build manufacturing capacity for an initial 5,000 RxT21 machines by FY26

Renalyx Health Systems has launched the country’s first indigenously developed, AI-powered smart hemodialysis machine to make renal care more affordable and accessible for patients with End-Stage Renal Disease (ESRD) across India.

Named RxT21, the cloud-enabled machine offers real-time remote monitoring and clinical connectivity and is priced at INR 6.7 lakh, 20–25% lower than comparable imported models, according to the company.

The launch is part of Renalyx’s broader plan to strengthen India’s kidney care infrastructure and address the growing burden of Chronic Kidney Disease (CKD).

The Bengaluru-based company has also announced plans to invest INR 800 Cr over the next four years to build manufacturing capacity for an initial 5,000 RxT21 machines by FY26, with an additional 1,500 units by FY28. The company will also manufacture associated consumables locally.

“Going forward, we plan to scale up our manufacturing capacity and reduce the total cost of ownership of the RxT21 by 40 per cent compared to imported machines. We also aim to develop a broader range of technologically advanced devices over the next three years, including a home dialysis model,” said Shyam Vasudeva Rao, Founder and Director of Renalyx Health Systems.

Renalyx currently operates manufacturing facilities in Bengaluru, Mysuru, and Mumbai to support its production scale-up. The company expects CDSCO approval for RxT21 by July 2025 and USFDA approval by March 2026.

The company also aims to align with the government’s ‘Make in India, Make for the World’ vision by exporting its machines to international markets and becoming a leading global player in renal care solutions within the next five years.

“RxT21 would bring dialysis closer to patients’ homes, helping reduce dropout rates,” Rao added.

Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All

Sign In / Sign up